Catherine Stehman-Breen, M.D.Dr. Catherine Stehman-Breen is Obsidian’s Chief Development Officer. Dr. Stehman-Breen brings over 15 years of experience in preclinical and clinical drug development including extensive knowledge of clinical development and regulatory affairs. She was most recently an Entrepreneur-In-Residence at Atlas Venture, where she served as the Chief Medical Officer of Dyne Therapeutics and Disarm Therapeutics. Prior to her role with Atlas, Dr. Stehman-Breen served as the Chief Medical Officer of Sarepta Therapeutics. Before that, she was the Vice President of Global Development and Regulatory Affairs at Regeneron Pharmaceuticals, Inc. She also served as Vice President, Global Development, at Amgen, leading several therapeutic areas. Dr. Stehman-Breen holds a B.A. in Biology and Psychology from Colby College, an M.S. in Epidemiology from the University of Washington and an M.D. from the University of Chicago, Pritzker School of Medicine.
< Back to Management